title: [Present status in hematopoietic stem cell transplantation (discussion)].
authors.forename: Shunichi
authors.initials: S
authors.lastname: Kato
authors.forename: Hideki
authors.initials: H
authors.lastname: Akiyama
authors.forename: Masaharu
authors.initials: M
authors.lastname: Kasai
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kanda
mesh_terms: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001549:Benzamides; D006086:Graft vs Host Disease; D016179:Granulocyte Colony-Stimulating Factor; D006680:HLA Antigens; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000639:trends; D006648:Histocompatibility; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents; D009894:Opportunistic Infections; D010879:Piperazines; D011743:Pyrimidines; D000069283:Rituximab; D014019:Tissue Donors; D009927:Tissue and Organ Procurement; D019172:Transplantation Conditioning; D014181:Transplantation Immunology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001549:Benzamides; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D016179:Granulocyte Colony-Stimulating Factor; D000069283:Rituximab; D000068877:Imatinib Mesylate